within Pharmacolibrary.Drugs.ATC.G;

model G04BD08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00015833333333333332,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.6,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00031666666666666665,
    Tlag           = 0,            
    Vdp             = 0.756,
    k12             = 47,
    k21             = 47
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BD08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Solifenacin is an antimuscarinic medication used primarily for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and incontinence. It is an approved prescription drug and widely used in clinical practice to manage symptoms of urinary incontinence.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li><p>Doroshyenko, O, &amp; Fuhr, U (2009). Clinical pharmacokinetics and pharmacodynamics of solifenacin. <i>Clinical pharmacokinetics</i> 48(5) 281–302. DOI:<a href=\"https://doi.org/10.2165/00003088-200948050-00001\">10.2165/00003088-200948050-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19566112/\">https://pubmed.ncbi.nlm.nih.gov/19566112</a></p></li><li><p>Tannenbaum, S, et al., &amp; Newgreen, D (2020). Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. <i>Pharmacology research &amp; perspectives</i> 8(6) e00684–None. DOI:<a href=\"https://doi.org/10.1002/prp2.684\">10.1002/prp2.684</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33231929/\">https://pubmed.ncbi.nlm.nih.gov/33231929</a></p></li><li><p>Kreder, KJ (2006). Solifenacin. <i>The Urologic clinics of North America</i> 33(4) 483–ix. DOI:<a href=\"https://doi.org/10.1016/j.ucl.2006.06.008\">10.1016/j.ucl.2006.06.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17011384/\">https://pubmed.ncbi.nlm.nih.gov/17011384</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BD08;
